Brainomix

medical devices

About

Brainomix is a medical software company founded in 2010 as a spin-out from the University of Oxford. The company specializes in AI-powered imaging biomarkers that enhance precision medicine and improve treatment decisions for patients worldwide. Its flagship product, Brainomix 360 Stroke, is an AI imaging platform that automates validated imaging biomarkers to support clinicians in acute stroke care, enabling faster and more confident decision-making. Brainomix focuses on providing advanced imaging solutions for healthcare providers, hospitals, and healthcare systems globally. The company collaborates with pharmaceutical companies to support clinical trials and therapeutic development by offering imaging biomarkers. Under the leadership of CEO Dr. Michalis Papadakis, Brainomix has achieved significant growth, received regulatory approvals, including FDA clearance in 2023, and continues to expand its AI technology into other therapeutic areas.

Technologies

Salesforce Route 53 Amazon SES Outlook Microsoft Azure Hosting Atlassian Cloud Microsoft Azure reCAPTCHA Google Tag Manager Hotjar Microsoft-IIS Bootstrap Framework Typekit ASP.NET Mobile Friendly Shutterstock Vimeo Google Play YouTube WordPress.org

Keywords

healthcare ai stroke interstitial lung disease medical medical devices health care medical equipment manufacturing stroke treatment optimization solid tumor imaging ai-powered medical devices ai clinical solutions predictive analytics ai-based treatment decisions services ai for medical workflows business intelligence ai in healthcare systems ai medical technology ai for neurological disorders ai biomarkers for lung fibrosis lung fibrosis assessment ai for healthcare providers automated stroke detection b2b healthtech ai solutions ai in stroke management ai for personalized treatment ai for healthcare innovation stroke diagnosis software

Location

West Way, Oxford, England, United Kingdom, OX2 0PH

Related Companies

Companies in the same industry